Pharmaceutical News and Articles
Clinical Trial Results
This section provides information about recently completed clinical trials. If you cannot find information about a particular clinical trial, you should note that results may not be available even after the trial ends. Some trials end before completion and results are never published.
Data Supports Compound's Potential as a Countermeasure for
Chlorine Gas Exposure
MISSION VIEJO, Calif.--(BUSINESS WIRE)--Nov 4, 2009 - Aeolus
Pharmaceuticals, Inc. (OTCBB: AOLS) reported that researchers from
National Jewish Health and McGill...
MALVERN, Pa.--(BUSINESS WIRE)--Nov 4, 2009 - Promedior, Inc., a
leader in the development of novel therapeutics for the treatment
of fibrotic diseases and tissue remodeling, announced today the
publication of results from preclinical studies...
LANGHORNE, Pa., Nov. 4 /PRNewswire/ -- EUSA Pharma announced
that PROSTASCINT® (capromab pendetide) fusion imaging was shown
to effectively guide prostate cancer therapy targeting and dosing
and is a significant predictor of disease free...
STOCKHOLM, Nov. 4, 2009--Data were presented from the phase IIa
trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of
the American Association for the Study of Liver Diseases in Boston,
USA.
TMC435 is an investigational protease...
- Significant antiviral potency in both naive and
treatment-failure patients -
BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- InterMune, Inc.
(Nasdaq: ITMN) and Pharmasset, Inc. (Nasdaq: VRUS) today...
Top-line Results Show Each Trial Met Primary and All Secondary
Endpoints
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Nov 3, 2009 -
Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE:
FRX) today announced positive top-line...
~Paper Features Design and Preclinical Characterization of
AP24534
~ Data Demonstrate Inhibition of all Known Variants of the
CML Target Protein
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 2, 2009 - ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA)...
--In Vitro Results presented in a poster session at
AASLD; Phase 2 combination studies to be initiated in 2Q
2010--
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nov 3, 2009 -
Drug discovery company SCYNEXIS, Inc. today presented positive...
BERLIN--(BUSINESS WIRE)--Nov 3, 2009 - MagForce Nanotechnologies
AG has successfully completed its single-arm clinical trial on the
efficacy of thermotherapy using superparamagnetic nanoparticles in
patients with recurrent glioblastoma. The...
- IMO-2125 Induces Endogenous Interferons and Other Antiviral
Proteins -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 3, 2009 - Idera
Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical
data on the mechanism by which IMO-2125 was shown...
Discovery may also have impact on the use of new drugs for
wet macular degeneration
BOSTON, Nov. 2 /PRNewswire-USNewswire/ -- Scientists at Schepens
Eye Research Institute have found that when the eye is missing a
diffusible form of vascular...
The two-dose meningococcal quadrivalent conjugate vaccine was
generally well-tolerated
PHILADELPHIA, Nov. 2 /PRNewswire/ -- Sanofi Pasteur, the
vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE:
SNY), presented Safety of a...
FRAZER, Pa., Nov. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc.
(Nasdaq: CEPH) today announced that the November issue of Mayo
Clinic Proceedings has published data from a pivotal Phase III
trial demonstrating that NUVIGIL® (armodafinil) Tablets...
Interim results of Phase IIa NEXT-I study
presented at American Association for the Study of Liver Diseases
(AASLD) Annual Meeting
BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough
Corporation (NYSE: SGP) today reported that interim...
Data to be presented at Infectious Diseases Society of
America Conference
EMERYVILLE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- NovaBay
Pharmaceuticals, Inc. (NYSE-Amex: NBY) today announced that its
Aganocide® compounds demonstrate potent...
— Data Presented at the 42nd
Annual Meeting of the American Society of Nephrology
—
SAN FRANCISCO--(BUSINESS WIRE)--Nov 2, 2009 - FibroGen, Inc.
today announced that new research on its therapeutic development
programs in kidney disease...
Study Addresses Unmet Medical Need for Difficult-to-Treat
Patient Population
BOSTON--(BUSINESS WIRE)--Oct 31, 2009 - Bristol-Myers Squibb
(NYSE: BMY) today announced 48-week data from an ongoing study
(ETV-048) of chronic hepatitis B...
Antiviral activity seen at all dose levels
tested
Results support moving to dose-ranging Phase II studies in
treatment-naïve HCV patients
PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Oct 31, 2009 -
Bristol-Myers Squibb Company (NYSE:...
No Evidence of Viral Resistance Through Three Years of
Treatment
BOSTON--(BUSINESS WIRE)--Oct 31, 2009 - Gilead Sciences, Inc.
(Nasdaq:GILD) today announced the presentation of three-year
(144-week) open label data from two pivotal Phase III...
BOSTON--(BUSINESS WIRE)--Nov 2, 2009 - Enzo Biochem Inc.
(NYSE:ENZ) announced today that favorable results of the Company's
clinical trial for treatment of non-alcoholic steatohepatitis
(NASH) were presented at the annual meeting of the...
More...
